Shandong Keyuan Pharmaceutical Shareholder Zeihong Completes Share Reduction; Total Reduction of 1.0829 Million Shares Representing 1% of Total Share Capital

On March 12, Shandong Keyuan Pharmaceutical Co., Ltd. (hereinafter referred to as “Shandong Keyuan Pharmaceutical”) announced that shareholders Wen Zehong and his concerted action partner Jiang Chunmei have completed their previously disclosed share reduction plan, totaling 1,082,900 shares, accounting for 1.0000% of the company’s total share capital.

Implementation of the reduction plan: completed in two phases with an average price range of 35.33 to 44.30 yuan

The announcement shows that Wen Zehong’s reduction plan was pre-disclosed on January 19, 2026. The plan was to reduce no more than 1,082,900 shares (1% of the total share capital) through centralized bidding within three months after the disclosure date, during fifteen trading days. Recently, the company received a notice from Wen Zehong stating that the share reduction plan has been completed.

Specifically, Wen Zehong carried out the reduction in two stages:

The shares sold in this reduction came from shares issued before the company’s initial public offering.

Shareholding changes before and after the reduction: total shareholding ratio decreased from 5.26% to 4.26%

The announcement also disclosed the shareholding status of Wen Zehong and his concerted action partner Jiang Chunmei before and after the reduction. Before the reduction, they held a total of 5,697,200 shares, accounting for 5.26% of the total share capital; after the reduction, their combined holdings decreased to 4,614,300 shares, or 4.26%. Details are as follows:

Impact on the company: no change in control rights; compliance assured

Shandong Keyuan Pharmaceutical emphasized in the announcement that Wen Zehong and his concerted action partner Jiang Chunmei have no related-party relationship with the company’s controlling shareholders or actual controllers. This reduction will not lead to a change in the company’s control, nor will it affect corporate governance or ongoing operations.

Additionally, the reduction strictly complies with the requirements of the Securities Law, the Shenzhen Stock Exchange Listing Company Self-Regulation Guidelines, and other relevant laws and regulations. The pre-disclosure was completed as required, the actual reduction was consistent with the plan, and no violations occurred. The shareholders also did not breach any commitments made during the company’s initial public offering.

As of the disclosure date, the plan has expired, and the actual shares reduced did not exceed the planned maximum.

Disclaimer: The market involves risks; investment should be cautious. This article is automatically published by an AI model based on third-party databases and does not represent Sina Finance’s views. All information herein is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for accuracy. For questions, contact biz@staff.sina.com.cn.

Click here to view the original announcement>>